Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:50:47 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:MYGN - MYRIAD GENETICS INC - http://www.myriad.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MYGN - Q1.318.49·18.500.218.49-0.02-0.1122.02,1571,48318.42  18.685  18.3824.21  13.8212:32:45Apr 1715 min RT 2¢

Recent Trades - Last 10 of 1483
Time ETExPriceChangeVolume
12:32:45Q18.495-0.01516
12:32:41Q18.495-0.0156
12:32:39Q18.495-0.0151
12:32:26Q18.495-0.0151
12:32:26Q18.495-0.0151
12:32:25Q18.495-0.0151
12:32:09Q18.495-0.0155
12:32:09Q18.495-0.0151
12:32:07Q18.495-0.0151
12:31:53Q18.495-0.0151

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-17 08:00U:MYGNNews ReleaseNearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
2024-04-16 09:15U:MYGNNews ReleaseNew Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel(TM) Prenatal Screen
2024-04-09 08:00U:MYGNNews ReleaseMyriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
2024-03-21 21:40U:MYGNNews ReleaseMyriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
2024-03-20 16:05U:MYGNNews ReleaseMyriad Genetics Announces Patent Granted for SneakPeek(TM) Snap Device
2024-02-27 16:05U:MYGNNews ReleaseMyriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the F
2024-02-27 09:15U:MYGNNews ReleaseMyriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
2024-02-21 16:05U:MYGNNews ReleaseMyriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2024-02-15 16:05U:MYGNNews ReleaseMyriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women ¢ € ™s Health
2024-02-01 09:25U:MYGNNews ReleaseMyriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
2024-01-30 17:00U:MYGNNews ReleaseMyriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
2024-01-18 18:10U:MYGNNews ReleaseMyriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
2024-01-09 16:05U:MYGNNews ReleaseMyriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
2024-01-03 16:05U:MYGNNews ReleaseMyriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-21 08:30U:MYGNNews ReleaseMyriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
2023-12-20 08:00U:MYGNNews ReleaseMyriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
2023-12-07 17:49U:MYGNNews ReleaseLevi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement
2023-12-05 12:02U:MYGNNews ReleaseLevi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. (MYGN) an Upcoming Claims Deadline in a Class Action Settlement
2023-11-20 16:05U:MYGNNews ReleaseMyriad Genetics Celebrates One Million SneakPeek ‚ ® Results Shared with Expectant Parents
2023-11-16 16:05U:MYGNNews ReleaseMyriad Genetics and Personalis Partner to Market Solutions ‚  to Pharma Customers